Skip to main content

Articles

Page 1 of 9

  1. Immunotherapies have emerged as potential treatments for metastatic castration-resistant prostate cancer (mCRPC). However, it is still unclear to identify the efficacy and safety of immunotherapy in large-scal...

    Authors: Anqiang Zhang and Dali Tong
    Citation: Experimental Hematology & Oncology 2022 11:63
  2. Increasing evidence of association between kidney stone disease (KSD) and renal cell carcinoma (RCC) has been reported. Nevertheless, mechanism underlying such association remained unknown. Herein, we investig...

    Authors: Paleerath Peerapen, Wanida Boonmark, Pattaranit Putpeerawit and Visith Thongboonkerd
    Citation: Experimental Hematology & Oncology 2022 11:62
  3. Cellular immunotherapy, including the chimeric antigen receptor T (CAR-T) cell therapy and CAR- natural killer (CAR-NK) cell therapy, has undergone extensive clinical investigation and development in recent ye...

    Authors: Ji-nuo Wang, Tianning Gu, Yongxian Hu and He Huang
    Citation: Experimental Hematology & Oncology 2022 11:61
  4. Targeting B-cell receptor signalling using Bruton tyrosine kinase (BTK) inhibitors (BTKis) has become a highly successful treatment modality for B-cell malignancies, especially for chronic lymphocytic leukaemi...

    Authors: Haoran Wang, Hao Guo, Jingyi Yang, Yanyan Liu, Xingchen Liu, Qing Zhang and Keshu Zhou
    Citation: Experimental Hematology & Oncology 2022 11:60
  5. The prognosis of most thyroid cancer patients is excellent, but for those with advanced or metastatic thyroid cancer, effective treatments are still lacking. Chimeric antigen receptor (CAR) T-cell therapy has ...

    Authors: Jing Ding, Deyu Li, Xingchen Liu, Hu Hei, Baoxi Sun, Dongmin Zhou, Keshu Zhou and Yongping Song
    Citation: Experimental Hematology & Oncology 2022 11:59
  6. Clonal hematopoiesis of indeterminate potential (CHIP) is associated with a small risk of developing hematologic malignancies and a higher risk of cardiovascular diseases (CVD). We asked whether the reverse co...

    Authors: Wei Qiao, Elliana Young, Chun Feng, Suyu Liu, Jeff Jin, Laila Noor, Cristhiam M. Rojas Hernandez, Gautam Borthakur, Olga Gorlova and Vahid Afshar-Kharghan
    Citation: Experimental Hematology & Oncology 2022 11:58
  7. The combination of rituximab, lenalidomide, and Bruton’s tyrosine kinase inhibitor (BTKi) ibrutinib, followed by chemotherapy, has shown high efficacy in patients with newly diagnosed diffuse large B-cell lymp...

    Authors: Yanan Zhu, Xiang Zhang, Juying Wei, Chunmei Yang, Hongyan Tong, Wenyuan Mai, Min Yang, Jiejing Qian, Liping Mao, Haitao Meng, Jie Jin and Wenjuan Yu
    Citation: Experimental Hematology & Oncology 2022 11:57
  8. The bone marrow is the place of hematopoiesis with a microenvironment that supports lifelong maintenance of stem cells and high proliferation. It is not surprising that this environment is also favourable for ...

    Authors: Lorenz Nierves, Jian Guo, Siyuan Chen, Janice Tsui, Anuli C. Uzozie, Jonathan W. Bush, Tao Huan and Philipp F. Lange
    Citation: Experimental Hematology & Oncology 2022 11:56
  9. In this study, we aimed to perform a pan-cancer analysis of leucine zipper protein 2 (LUZP2). A standardized TCGA pan-cancer dataset was downloaded. Differential expression, clinical prognosis, genetic mutatio...

    Authors: Dechao Feng, Xu Shi, Weizhen Zhu, Facai Zhang, Dengxiong Li, Ping Han, Qiang Wei and Lu Yang
    Citation: Experimental Hematology & Oncology 2022 11:55
  10. Activating G protein-coupled estrogen receptor 1 (GPER1) is an attractive therapeutic strategy for treating a variety of human diseases including cancer. Here, we show that GPER1 is significantly upregulated i...

    Authors: Eugenio Morelli, Zachary R. Hunter, Mariateresa Fulciniti, Annamaria Gullà, Ida Daniela Perrotta, Valeria Zuccalà, Cinzia Federico, Giada Juli, Martina Manzoni, Domenica Ronchetti, Enrica Romeo, Maria Eugenia Gallo Cantafio, Debora Soncini, Lorenza Maltese, Marco Rossi, Aldo M. Roccaro…
    Citation: Experimental Hematology & Oncology 2022 11:54
  11. Because prolonged viral replication of SARS-CoV-2 is increasingly being recognized among immunocompromised patients, subacute or chronic COVID-19 pneumonia can cause persistent lung damage and may lead to vira...

    Authors: Daiki Wada, Yasushi Nakamori, Shuhei Maruyama, Haruka Shimazu, Fukuki Saito, Kazuhisa Yoshiya and Yasuyuki Kuwagata
    Citation: Experimental Hematology & Oncology 2022 11:53
  12. Early evidence indicated that cancer patients are at increased risk of adverse outcomes and mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. To determine the putative mec...

    Authors: Jingwen Deng, Xiaopeng Cai and Zhi Chen
    Citation: Experimental Hematology & Oncology 2022 11:52
  13. Circular RNAs (circRNAs) play a critical role in the modulation of tumor metabolism. However, the expression patterns and metabolic function of circRNAs in chronic lymphocytic leukemia (CLL) remain largely unk...

    Authors: Zijuan Wu, Danling Gu, Ruixin Wang, Xiaoling Zuo, Huayuan Zhu, Luqiao Wang, Xueying Lu, Yi Xia, Shuchao Qin, Wei Zhang, Wei Xu, Lei Fan, Jianyong Li and Hui Jin
    Citation: Experimental Hematology & Oncology 2022 11:51
  14. Minimal residual disease (MRD) is considered the strongest relevant predictor of prognosis and an effective decision-making factor during the treatment of hematological malignancies. Remarkable breakthroughs b...

    Authors: Xinyue Deng, Meilan Zhang, Jianfeng Zhou and Min Xiao
    Citation: Experimental Hematology & Oncology 2022 11:50
  15. Cancer cells are well-known for their capacity to adapt their metabolism to their increasing energy demands which is necessary for tumor progression. This is no different for Multiple Myeloma (MM), a hematolog...

    Authors: Inge Oudaert, Arne Van der Vreken, Anke Maes, Elke De Bruyne, Kim De Veirman, Karin Vanderkerken and Eline Menu
    Citation: Experimental Hematology & Oncology 2022 11:49
  16. Primary immune thrombocytopenia (ITP) is an autoimmune disease. Some ITP patients are associated with pathogen infection undetected with conventional technologies. Investigating the changes of T cells and pote...

    Authors: Yanxia Zhan, Jingjing Cao, Lili Ji, Miaomiao Zhang, Qi Shen, Pengcheng Xu, Xibing Zhuang, Shanshan Qin, Fanli Hua, Lihua Sun, Feng Li, Hao Chen and Yunfeng Cheng
    Citation: Experimental Hematology & Oncology 2022 11:48
  17. Erythrocytosis is a clinical condition characterized by increased red cell mass, hemoglobin, and hematocrit values. A significant fraction of patients is described as having idiopathic erythrocytosis. We have ...

    Authors: Antonella Zagaria, Francesco Tarantini, Paola Orsini, Luisa Anelli, Cosimo Cumbo, Nicoletta Coccaro, Giuseppina Tota, Crescenzio Francesco Minervini, Elisa Parciante, Maria Rosa Conserva, Immacolata Redavid, Alessandra Ricco, Immacolata Attolico, Giorgina Specchia, Pellegrino Musto and Francesco Albano
    Citation: Experimental Hematology & Oncology 2022 11:47
  18. Patients receiving hematopoietic stem cell transplantation (HSCT) or chimeric antigen receptor T cell (CAR T-cell) therapy are immunocompromised and at high risk of viral infection, including SAR2-CoV-2 infect...

    Authors: Chenghao Ge, Kelei Du, Mingjie Luo, Kaini Shen, Yangzhong Zhou, Kaiyuan Guo, Yang Liu, Chen Yin, Yi Li, Guanqiao Li and Xiaoyuan Chen
    Citation: Experimental Hematology & Oncology 2022 11:46
  19. The N(6)-methyladenosine (m6A) modification is the most pervasive modification of human RNAs. In recent years, an increasing number of studies have suggested that m6A likely plays important roles in cancers. M...

    Authors: Zhen Fang, Wentong Mei, Chang Qu, Jiongdi Lu, Liang Shang, Feng Cao and Fei Li
    Citation: Experimental Hematology & Oncology 2022 11:45
  20. The molecular mechanisms underlying cancer immune escape are a core topic in cancer immunology research. Cancer cells can escape T cell-mediated cellular cytotoxicity by exploiting the inhibitory programmed ce...

    Authors: Zhuandi Liu, Xibao Yu, Ling Xu, Yangqiu Li and Chengwu Zeng
    Citation: Experimental Hematology & Oncology 2022 11:44
  21. Pyruvate kinase M2 (PKM2) plays an important role in the metabolism and proliferation of leukemia cells. Here, we show that deubiquitinase JOSD2, a novel tumor suppressor, blocks PKM2 nuclear localization by r...

    Authors: Hu Lei, Li Yang, Yingying Wang, Zhihui Zou, Meng Liu, Hanzhang Xu and Yingli Wu
    Citation: Experimental Hematology & Oncology 2022 11:42
  22. Cancer stem cells (CSCs) have been identified in multiple myeloma (MM) and are widely regarded as a key driver of MM initiation and progression. E-cadherin, in addition to its established role as a marker for ...

    Authors: Parinya Samart, Yon Rojanasakul, Surapol Issaragrisil and Sudjit Luanpitpong
    Citation: Experimental Hematology & Oncology 2022 11:41
  23. Mantle cell lymphoma (MCL) is a rare, highly heterogeneous type of B-cell non-Hodgkin’s lymphoma. The sumoylation pathway is known to be upregulated in many cancers including lymphoid malignancies. However, li...

    Authors: Walter Hanel, Pushpa Lata, Youssef Youssef, Ha Tran, Liudmyla Tsyba, Lalit Sehgal, Bradley W. Blaser, Dennis Huszar, JoBeth Helmig-Mason, Liwen Zhang, Morgan S. Schrock, Matthew K. Summers, Wing Keung Chan, Alexander Prouty, Bethany L. Mundy-Bosse, Selina Chen-Kiang…
    Citation: Experimental Hematology & Oncology 2022 11:40
  24. Metabolic reprogramming, fundamentally pivotal in carcinogenesis and progression of cancer, is considered as a promising therapeutic target against tumors. In chronic lymphocytic leukemia (CLL) cells, metaboli...

    Authors: Yu Nie, Xiaoya Yun, Ya Zhang and Xin Wang
    Citation: Experimental Hematology & Oncology 2022 11:39
  25. T cell immunotherapy remains an attractive approach for cancer immunotherapy. T cell immunotherapy mainly employs chimeric antigen receptor (CAR)- and T cell receptor (TCR)-engineered T cells. CAR-T cell thera...

    Authors: Yikai Zhang, Zhipeng Liu, Wei Wei and Yangqiu Li
    Citation: Experimental Hematology & Oncology 2022 11:38
  26. The application of hematopoietic stem cells (HSCs) has been restricted due to limited cell sources and conventional methods for generating these cells by cell expansion and pluripotent stem cell differentiatio...

    Authors: Liaoliao Dong, Chuijin Wei, Shumin Xiong, Ping Yu, Ren Zhou and Lin Cheng
    Citation: Experimental Hematology & Oncology 2022 11:37
  27. Tyrosine kinase inhibitors have achieved quite spectacular advances in the treatment of chronic myeloid leukemia (CML), but disease progression and drug resistance that related to the T315I mutation, remain ma...

    Authors: Zhuanyun Du, Zhenglan Huang, Xi Chen, Guoyun Jiang, Yuhang Peng, Wenli Feng and Ningshu Huang
    Citation: Experimental Hematology & Oncology 2022 11:36
  28. Transfer RNAs (tRNAs) promote protein translation by binding to the corresponding amino acids and transporting them to the ribosome, which is essential in protein translation. tRNA-derived small RNAs (tsRNAs) ...

    Authors: Xinliang Gu, Yu Zhang, Xinyue Qin, Shuo Ma, Yuejiao Huang and Shaoqing Ju
    Citation: Experimental Hematology & Oncology 2022 11:35
  29. Chronic graft-versus-host disease (cGVHD) remains a major complication during the late phase of allogeneic hematopoietic stem cell transplantation (allo-HSCT). IL-39, a newly described pro-inflammatory cytokin...

    Authors: Kangkang Lv, Bo Hu, Mingzhu Xu, Li Wan, Ziqi Jin, Mimi Xu, Yuanyuan Du, Kunpeng Ma, Quansheng Lv, Yang Xu, Lei Lei, Huanle Gong, Haiyan Liu, Depei Wu and Yuejun Liu
    Citation: Experimental Hematology & Oncology 2022 11:34
  30. With the widespread clinical application of tyrosine kinase inhibitors (TKIs), an increasing number of chronic myeloid leukaemia (CML) patients have developed resistance or intolerance to TKIs. BCR/ABL is the ...

    Authors: Dachuan Zeng, Miao Gao, Renren Zheng, Run Qin, Wei He, Suotian Liu, Wei Wei and Zhenglan Huang
    Citation: Experimental Hematology & Oncology 2022 11:33
  31. Chronic myelomonocytic leukemia (CMML) is a rare and heterogeneous hematological malignancy. It has been shown that the molecular abnormalities such as ASXL1, TET2, SETBP1, and SRSF2 mutations are common in Cauca...

    Authors: Yanbo Nie, Liang Shao, Hong Zhang, Colin K. He, Hongyu Li, Junyan Zou, Long Chen, Huaiyue Ji, Hao Tan, Yani Lin and Kun Ru
    Citation: Experimental Hematology & Oncology 2022 11:32
  32. As the most common and abundant RNA modification in eukaryotic cells, N6-methyladenosine (m6A) modification plays an important role in different stages of tumor. m6A can participate in the regulation of tumor ...

    Authors: Ze Zhang, Furong Liu, Wei Chen, Zhibin Liao, Wanguang Zhang, Bixiang Zhang, Huifang Liang, Liang Chu and Zhanguo Zhang
    Citation: Experimental Hematology & Oncology 2022 11:30
  33. Leukemia stem cells (LSCs) are responsible for the initiation and perpetuation of acute myeloid leukemia (AML), and also represent leukemia relapse reservoirs with limited therapeutic approaches. Thus, additio...

    Authors: Haijun Zhao, Yuelong Jiang, Fusheng Lin, Mengya Zhong, Jinshui Tan, Yong Zhou, Long Liu, Guowei Li, Manman Deng and Bing Xu
    Citation: Experimental Hematology & Oncology 2022 11:29
  34. Myelodysplastic syndromes (MDS) are generally considered as a group of clonal diseases derived from hematopoietic stem cells, but a number of studies have suggested that they are derived from myeloid progenito...

    Authors: Bingqing Luo, Fang Dong, Tiejun Qin, Qingyun Zhang, Haitao Bai, Jinhong Wang, Yujiao Jia, Shihui Ma, Erlie Jiang, Tao Cheng, Zhijian Xiao and Hideo Ema
    Citation: Experimental Hematology & Oncology 2022 11:28
  35. Engineered T cells have been shown to be highly effective in cancer immunotherapy, although T cell exhaustion presents a challenge for their long-term function. Additional T-cell sources must be exploited to b...

    Authors: Rongqun Guo, Wei Li, Yadan Li, Yingmei Li, Zhongxing Jiang and Yongping Song
    Citation: Experimental Hematology & Oncology 2022 11:27
  36. CD47/SIRPα axis is recognized as an innate immune checkpoint and emerging clinical data validate the interest of interrupting this pathway in cancer, particularly in hematological malignancies. In preclinical ...

    Authors: Xavier Chauchet, Laura Cons, Laurence Chatel, Bruno Daubeuf, Gérard Didelot, Valéry Moine, Didier Chollet, Pauline Malinge, Guillemette Pontini, Krzysztof Masternak, Walter Ferlin, Vanessa Buatois and Limin Shang
    Citation: Experimental Hematology & Oncology 2022 11:26
  37. Acute graft-versus-host disease (aGVHD) remains the major cause of early mortality after haploidentical related donor (HID) hematopoietic stem cell transplantation (HSCT). We aimed to establish a comprehensive...

    Authors: Meng-Zhu Shen, Shen-Da Hong, Rui Lou, Rui-Ze Chen, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Kai-Yan Liu, Xiao-Jun Huang and Xiao-Dong Mo
    Citation: Experimental Hematology & Oncology 2022 11:25
  38. Dysregulation of MDM2, a p53 negative regulator, frequently occurs in acute myeloid leukemia (AML) and is associated with unfavorable prognoses, rendering the p53-MDM2 axis an attractive target for the develop...

    Authors: Qinwei Chen, Suqi Deng, Manman Deng, Yuanfei Shi, Mengya Zhong, Lihong Ding, Yuelong Jiang, Yong Zhou, Bing Z. Carter and Bing Xu
    Citation: Experimental Hematology & Oncology 2022 11:23
  39. Very few reports elucidate the prognosis of patients with TP53 aberrations using both measurable residual disease (MRD) and the status of having undergone allogeneic hematopoietic stem cell transplantation (allo-...

    Authors: Qiuyun Fang, Xiaoyuan Gong, Kaiqi Liu, Yujiao Jia, Yang Song, Guangji Zhang, Yan Li, Qishan Hao, Yueshen Ma, Shuning Wei, Bingcheng Liu, Ying Wang, Hui Wei, Jianxiang Wang and Yingchang Mi
    Citation: Experimental Hematology & Oncology 2022 11:22
  40. YT521-B homology domain family member 2 (YTHDF2) is an N6-methyladenosine (m6A)-binding protein that was originally found to regulate the stability of mRNA. Growing evidence has shown that YTHDF2 can participate ...

    Authors: Xiaomin Chen, Xiangxiang Zhou and Xin Wang
    Citation: Experimental Hematology & Oncology 2022 11:21
  41. Physical activity is known to have anti-cancer effects, including immunomodulatory actions. This study investigated the hypothesis that physical activity synergizes with combined lenvatinib plus anti-PD-1 ther...

    Authors: Xue-Feng Liu, Xiao-Dong Zhu, Long-Hai Feng, Xiao-Long Li, Bin Xu, Kang-Shuai Li, Nan Xiao, Ming Lei, Hui-Chuan Sun and Zhao-You Tang
    Citation: Experimental Hematology & Oncology 2022 11:20
  42. The glycoprotein (GP) Ib-IX complex is a platelet receptor that mediates the initial interaction with subendothelial von Willebrand factor (VWF) causing platelet arrest at sites of vascular injury even under c...

    Authors: Gerd Bendas and Martin Schlesinger
    Citation: Experimental Hematology & Oncology 2022 11:19
  43. IRE1 is an unfolded protein response (UPR) sensor with kinase and endonuclease activity. It plays a central role in the endoplasmic reticulum (ER) stress response through unconventional splicing of XBP1 mRNA a...

    Authors: Dalia Quwaider, Luis A. Corchete, Marta Martín-Izquierdo, Jesús M. Hernández-Sánchez, Elizabeta A. Rojas, Ignacio J. Cardona-Benavides, Ramón García-Sanz, Ana B. Herrero and Norma C. Gutiérrez
    Citation: Experimental Hematology & Oncology 2022 11:18
  44. There are no head-to-head clinical studies comparing chimeric antigen receptor (CAR) T-cell therapies for the treatment of relapsed or refractory aggressive large B-cell lymphomas. Naive, indirect comparisons ...

    Authors: Guillaume Cartron, Christopher P. Fox, Fei Fei Liu, Ana Kostic, Jens Hasskarl, Daniel Li, Ashley Bonner, Yixie Zhang, David G. Maloney and John Kuruvilla
    Citation: Experimental Hematology & Oncology 2022 11:17
  45. An elevated platelet count has been associated with an increased incidence of cancer and poor survival for many cancer types. In this study, platelet levels were captured among cancer patients in the 2 years p...

    Authors: Vasily Giannakeas
    Citation: Experimental Hematology & Oncology 2022 11:16
  46. CD19 chimeric antigen receptor (CAR) therapy has achieved impressive success in relapsed or refractory (R/R) B-cell malignancies, but relapse due to antigen escape is increasingly appearing reported. As the ex...

    Authors: Yu Zhang, Saisai Li, Ying Wang, Yang Lu, Yingxi Xu, Qing Rao, Huijun Wang, Haiyan Xing, Zheng Tian, Kejing Tang, Lulu Lv, Min Wang and Jianxiang Wang
    Citation: Experimental Hematology & Oncology 2022 11:15
  47. N6-methyladenosine (m6A) RNA methylation and its methyltransferase METTL3 have been widely reported to be involved in different cancers by regulating RNA metabolism and function. Here, we aimed to explore the ...

    Authors: Yu-qing Guo, Qiang Wang, Jun-guo Wang, Ya-jun Gu, Pan-pan Song, Shou-yu Wang, Xiao-yun Qian and Xia Gao
    Citation: Experimental Hematology & Oncology 2022 11:14

Annual Journal Metrics